TNFRSF10D

TNFRSF10D (TRAIL-R4/DcR2) is a decoy receptor in the TRAIL death receptor pathway that antagonizes apoptosis through multiple mechanisms while simultaneously activating pro-survival signaling. It binds TRAIL via its extracellular domain but cannot transduce apoptotic signals due to a truncated intracellular death domain; instead, it inhibits apoptosis by competing with death receptors for TRAIL and by forming heteromeric complexes with TRAIL-R2/DR5 through its pre-ligand assembly domain (PLAD), with DcR2 exhibiting greater binding affinity for DR5 than for TRAIL itself (PMID:9430226, PMID:40154678). In a ligand-independent manner, TNFRSF10D activates NF-κB, AKT/PI3K, and ERK signaling to promote cell survival and proliferation, though stable knockdown reveals context-dependent effects whereby loss of DcR2 can paradoxically inhibit apoptosis in certain cell lines through compensatory Bcl-xL upregulation (PMID:21625476, PMID:36158196). Its expression is transcriptionally controlled by p53 (via an intronic p53-binding site) and androgens, post-transcriptionally repressed by PARP13-mediated mRNA decay, epigenetically silenced by promoter CpG hypermethylation in tumors, and regulated at the protein level by interferon-induced proteasomal degradation (PMID:16230375, PMID:16245307, PMID:25382312, PMID:11929838, PMID:16185657).

1. 1997 High

   The cloning of TRAIL-R4/DcR2 resolved how cells could bind TRAIL yet resist apoptosis, revealing a receptor that activates NF-κB but has a truncated death domain incapable of death signaling, thereby establishing the concept of a decoy receptor in the TRAIL system.

   Evidence Molecular cloning, NF-κB reporter assays, and transient overexpression protection against TRAIL-mediated killing; independently replicated

   PMID:9430226 PMID:9537512

   Open questions at the time

   • Mechanism by which DcR2 blocks signaling at death receptors was unknown beyond simple competition for ligand
   • Physiological expression patterns and transcriptional regulation uncharacterized
   • Whether DcR2 transmits any active survival signals beyond NF-κB was unknown
2. 2000 High

   Deletion mutagenesis of DcR2's intracellular domain distinguished two protective mechanisms: the extracellular domain sufficed to block TRAIL, but the first 43 amino acids of the ICD were specifically required for protection against p53- or KILLER/DR5-induced cell death, revealing that DcR2 is not simply a passive ligand sink.

   Evidence ICD deletion constructs co-expressed with p53 or KILLER/DR5, functional cell death assays

   PMID:10933923

   Open questions at the time

   • The signaling mechanism mediated by the proximal ICD fragment was not identified
   • Whether DcR2 physically interacts with DR5 was not tested
3. 2002 Medium

   The finding that DcR2 promoter hypermethylation silences its expression in neuroblastoma and other tumors, reversible by demethylating agents, explained how tumors can lose a decoy receptor and provided an epigenetic mechanism for altered TRAIL pathway sensitivity in cancer.

   Evidence Methylation-specific PCR, bisulfite sequencing, 5-aza-2'-deoxycytidine treatment restoring mRNA

   PMID:11929838

   Open questions at the time

   • Functional consequences of demethylation on TRAIL-induced apoptosis were not directly tested
   • Single-lab observation at this time; breadth across tumor types was limited
4. 2003 Medium

   Anti-DcR2 antibody blocking in osteosarcoma cells that had acquired DcR2 surface expression during passaging restored TRAIL sensitivity dose-dependently, providing the first loss-of-function evidence that endogenous DcR2 at the cell surface is a physiologically relevant barrier to TRAIL-induced apoptosis.

   Evidence Flow cytometry for DcR2 surface expression, anti-DcR2 blocking antibody, apoptosis assays

   PMID:12838325

   Open questions at the time

   • Mechanism of DcR2 upregulation during passaging was not determined
   • Antibody blocking does not distinguish competition for TRAIL from disruption of receptor–receptor complexes
5. 2005 High

   Identification of a direct p53-binding site in DcR2's first intron by ChIP and reporter assays established DcR2 as a bona fide p53 target gene, revealing a negative feedback loop in which p53-induced apoptosis is modulated by p53-driven expression of an anti-apoptotic decoy receptor.

   Evidence ChIP, luciferase reporter with p53BS, p53BS mutagenesis, siRNA knockdown with chemotherapy apoptosis assay

   PMID:16230375

   Open questions at the time

   • Whether p53-mediated DcR2 induction occurs in non-tumor physiological contexts was not shown
   • Relative contribution of p53-driven DcR2 vs. other p53 targets in modulating apoptotic outcome was unclear
6. 2005 Medium

   Demonstrating that interferons (IFNγ, IFNα) reduce DcR2 surface expression via proteasome-dependent degradation revealed a protein-level regulatory mechanism that sensitizes cells to TRAIL, complementing the known transcriptional and epigenetic controls.

   Evidence Flow cytometry, proteasome inhibitor MG132 rescue, siRNA-mediated DcR2 knockdown, TRAIL apoptosis assay

   PMID:16185657

   Open questions at the time

   • The E3 ubiquitin ligase responsible for DcR2 ubiquitylation was not identified
   • Whether interferon-induced degradation operates in vivo was not tested
7. 2006 Medium

   The finding that testosterone specifically maintains DcR2 expression in rat prostate (while other TRAIL receptors are unaffected) identified DcR2 as an androgen-regulated gene, providing a mechanism by which androgen deprivation therapy could sensitize prostate tissue to TRAIL-mediated apoptosis.

   Evidence Castration, testosterone replacement, flutamide treatment; RT-PCR and Western blot in rat ventral prostate

   PMID:16245307

   Open questions at the time

   • Whether androgen receptor directly binds the DcR2 promoter was not tested
   • Functional link between androgen-regulated DcR2 and TRAIL sensitivity in prostate was not demonstrated
8. 2011 High

   The discovery that TRAIL-R4 forms a heteromeric complex with TRAIL-R2 to reduce caspase-8 activation, and independently activates AKT/PI3K signaling to promote proliferation and tumor growth, established DcR2 as both a dominant-negative receptor and an active oncogenic signaling molecule.

   Evidence Ectopic TRAIL-R4 expression, caspase-8 assay, PI3K inhibition (LY294002, p85 siRNA, PTEN OE), xenograft model

   PMID:21625476

   Open questions at the time

   • The molecular mechanism linking DcR2's truncated death domain to PI3K/AKT activation was not resolved
   • The stoichiometry and structural basis of the TRAIL-R4/TRAIL-R2 heterocomplex were not determined
9. 2014 High

   Identification of PARP13 as a post-transcriptional repressor that binds the TRAILR4 3′ UTR and triggers exosome-dependent mRNA decay added an RNA regulatory layer to DcR2 control, explaining how cells can fine-tune TRAIL sensitivity independently of transcription.

   Evidence PARP13 siRNA knockdown, RNA-seq, RNA immunoprecipitation, exosome inhibition, TRAIL apoptosis assay

   PMID:25382312

   Open questions at the time

   • Specific RNA sequences/structures in the 3′ UTR recognized by PARP13 were not mapped
   • Whether PARP13-mediated DcR2 repression operates in non-cancer contexts was not explored
10. 2022 High

    Stable DcR2 knockdown in two cancer cell lines revealed that DcR2's role is context-dependent: pro-survival in one line (Colo357) but paradoxically pro-apoptotic in another (MDA-MB-231) via compensatory Bcl-xL upregulation, challenging a simple decoy receptor model and showing that DcR2 actively shapes the signaling landscape through NF-κB, AKT, and ERK pathways.

    Evidence Stable shRNA KD in Colo357 and MDA-MB-231, clonogenic assays, pathway Western blots, Navitoclax rescue of Bcl-xL-dependent survival

    PMID:36158196

    Open questions at the time

    • Mechanism by which DcR2 loss leads to Bcl-xL upregulation in MDA-MB-231 was not delineated
    • Which downstream effectors mediate the context-dependent switch was not resolved
11. 2025 High

    Demonstrating that DcR2 binds DR5 with higher affinity than TRAIL and that its PLAD domain is required for heterocomplex formation and cardioprotection in myocardial ischemia/reperfusion injury redefined DcR2 as a direct DR5 ligand/modulator acting through receptor–receptor interactions rather than solely through ligand sequestration.

    Evidence Affinity binding assays, PLAD deletion mutagenesis, hDcR2-Fc fusion protein, mouse myocardial I/R model

    PMID:40154678

    Open questions at the time

    • Structural basis of the PLAD-mediated DcR2–DR5 interaction at atomic resolution is unknown
    • Whether PLAD-dependent DR5 inhibition operates in tissues beyond the heart was not tested
    • Relative contribution of TRAIL sequestration vs. DR5 heterocomplexing in physiological settings remains unquantified

• Key open questions include the structural basis of DcR2–DR5 PLAD interaction, the signaling intermediates linking DcR2's truncated death domain to PI3K/AKT activation, and the molecular determinants that dictate context-dependent pro-survival versus pro-apoptotic outcomes upon DcR2 loss.
• No structural model of the DcR2–DR5 heterocomplex exists
• The adaptor proteins linking DcR2 to PI3K/AKT have not been identified
• In vivo genetic knockout models for DcR2 have not been reported